Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
07 Junio 2023 - 7:30AM
Artelo Biosciences,
Inc.
(
Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced
that it was selected for an oral presentation at the
33rd International Cannabinoid Research Society (ICRS)
Symposium being held on June 24-29, 2023 in Toronto, Ontario,
Canada, at the Marriott Downtown at CF Toronto Eaton Centre.
Professor Saoirse O’Sullivan, Vice President of Translational
Sciences at Artelo, is scheduled to present new data on ART12.11,
Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday,
June 25th at 9:15 EDT. Results from preclinical studies with
ART12.11 in stress-induced anxiety and depression that were
conducted at the laboratory of Professor Steven Laviolette at the
University of Western Ontario, Canada, will be presented by
Professor O’Sullivan as well as data related to ART12.11’s
pharmacokinetics as compared to other forms of CBD.
The medicinal potential of CBD has been established; however,
because it is poorly absorbed there have been challenges related to
the oral administration of CBD. Cocrystals are solid compositions
designed to improve the physical characteristics of a drug, which
can produce pharmaceutical, regulatory, and manufacturing
advantages. To date, Artelo has been issued four patents on its
cannabidiol cocrystal, including two patents from the U.S. Patent
and Trademark Office and two foreign patents, related to ART12.11’s
composition and methods of use.
“We are excited to share new, positive research results from our
ongoing preclinical development program with ART12.11,” said
Gregory D. Gorgas, President and Chief Executive Officer at Artelo.
“Our proprietary CBD cocrystal continues to be an important part of
the Company’s goals to bring novel and differentiated therapeutics
into the clinic to improve outcomes in patients with high unmet
needs such as anxiety and PTSD.”
About ART12.11ART12.11 is a proprietary
cocrystal composition of synthetic cannabidiol (CBD). The crystal
structure of CBD is known to exhibit solid polymorphism, or the
ability to manifest in different forms. Artelo’s patented cocrystal
is a single crystalline form and, as such, has advantages over
other compositions of CBD that exhibit solid polymorphism.
Preclinical studies of ART12.11 have exhibited superior
pharmacokinetics compared to other forms of CBD with improved
stability, solubility, and absorption profile. Artelo believes the
more consistent and improved bioavailability may ultimately lead to
improved safety and efficacy, thus making ART12.11 a preferred CBD
pharmaceutical composition.
About the International Cannabinoid Research
SocietyThe International Cannabinoid Research
Society (ICRS) is the premier global scientific association
with more than 650 international members from 40 countries, all
active researchers in the field of endogenous, plant-derived, and
synthetic cannabinoids and related bioactive lipids. In addition to
acting as a source for impartial information on cannabis and the
cannabinoids, the main role of the ICRS is to provide an open forum
for researchers to meet and discuss their research. The ICRS
Symposium is being held at the Marriott Downtown at CF Toronto
Eaton Centre, Toronto, Canada, from June 24-29, 2023.
Interested parties may follow @ICRS_Society on
Twitter.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024